Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,465.88 -3.42 (-0.06%) Dow
39,040.00 -72.16 (-0.18%) Nasdaq
17,770.69 +53.04 (+0.30%) Bitcoin USD
61,775.30 +61.07 (+0.10%) CMC Crypto 200
1,276.64 -7.15 (-0.56%)
ITCI Nov 2024 90.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:38PM EDT. Market open.
| Previous close | 3.0300 |
| Open | 3.0300 |
| Bid | 1.2500 |
| Ask | 2.3500 |
| Strike | 90.00 |
| Expiry date | 2024-11-15 |
| Day's range | 3.0300 - 3.0300 |
| Contract range | N/A |
| Volume | |
| Open interest | 432 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.